INT692

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1978
Last Reported 2010
Negated 4
Speculated 1
Reported most in Abstract
Documents 72
Total Number 73
Disease Relevance 28.68
Pain Relevance 34.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SST) extracellular region (SST) cell-cell signaling (SST)
Anatomy Link Frequency
plasma 3
hypothalamus 3
CSF 2
somatotrope 2
nerve 2
SST (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 525 100.00 Very High Very High Very High
Neuropeptide 26 100.00 Very High Very High Very High
Enkephalin 26 100.00 Very High Very High Very High
substance P 16 100.00 Very High Very High Very High
Morphine 9 99.98 Very High Very High Very High
Cholecystokinin 5 99.92 Very High Very High Very High
rheumatoid arthritis 22 99.84 Very High Very High Very High
Clonidine 81 99.82 Very High Very High Very High
Calcitonin gene-related peptide 4 99.80 Very High Very High Very High
Endogenous opioid 5 99.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 247 100.00 Very High Very High Very High
Acromegaly 35 100.00 Very High Very High Very High
Hypoxia 5 100.00 Very High Very High Very High
Diarrhoea 26 99.92 Very High Very High Very High
Hypoglycemia 48 99.90 Very High Very High Very High
Rheumatoid Arthritis 22 99.84 Very High Very High Very High
Disease 123 99.72 Very High Very High Very High
Diabetes Mellitus 22 99.68 Very High Very High Very High
Obesity 52 99.64 Very High Very High Very High
Headache 34 99.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The absence of any inhibitory effect of somatostatin and octreotide on electrogenic secretion in the human colon may explain the variable results obtained when somatostatin or octreotide are used for the treatment of secretory diarrheas.
Negative_regulation (effect) of somatostatin in colon associated with diarrhoea and somatostatin
1) Confidence 0.59 Published 2000 Journal Dig. Dis. Sci. Section Abstract Doc Link 11215722 Disease Relevance 0.15 Pain Relevance 0.45
These data suggest that MEL and pyridostigmine stimulate GH secretion through a common mechanism, which is probably represented by the inhibition of somatostatin activity.
Negative_regulation (inhibition) of somatostatin associated with somatostatin
2) Confidence 0.57 Published 1998 Journal Metab. Clin. Exp. Section Abstract Doc Link 9667227 Disease Relevance 0 Pain Relevance 0.35
It has been recently reported that pyridostigmine (PD), an indirect cholinergic agonist, probably acting via inhibition of hypothalamic somatostatin, potentiates the GH-releasing hormone (GHRH)-induced GH rise in men, but not in women.
Negative_regulation (inhibition) of somatostatin associated with somatostatin and agonist
3) Confidence 0.57 Published 1993 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8432781 Disease Relevance 0 Pain Relevance 0.10
The last phenomenon has been explained by an increase of somatostatin (being a natural TSH inhibitor) in the patients on rhGH therapy [15].
Negative_regulation (inhibitor) of somatostatin associated with somatostatin
4) Confidence 0.57 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.27 Pain Relevance 0.05
Serum somatostatin levels were reduced in RA patients between 45 and 55 yrs but reached a significant reduction (p less than 0.0001) in RA patients, 55 years and older compared to age-matched individuals from the control group.
Negative_regulation (reduced) of somatostatin associated with rheumatoid arthritis and somatostatin
5) Confidence 0.57 Published 2004 Journal Front. Biosci. Section Abstract Doc Link 14977577 Disease Relevance 0.88 Pain Relevance 0.67
Reduced somatostatin levels in older RA patients resulted in a skewed upward growth hormone to somatostatin ratio.
Negative_regulation (Reduced) of somatostatin associated with rheumatoid arthritis and somatostatin
6) Confidence 0.57 Published 2004 Journal Front. Biosci. Section Abstract Doc Link 14977577 Disease Relevance 0.88 Pain Relevance 0.82
As this effect is probably mediated by two different mechanisms, i.e. via increased endogenous GHRH for CLON and via inhibition of endogenous somatostatin for PD, in 8 normal children we studied the effect of both single and combined acute oral administration of CLON (150 micrograms/m2) and PD (60 mg).
Negative_regulation (inhibition) of somatostatin associated with somatostatin and clonidine
7) Confidence 0.57 Published 1989 Journal J. Endocrinol. Invest. Section Abstract Doc Link 2754188 Disease Relevance 0 Pain Relevance 0.78
Somatostatin is a potent inhibitor of gastrin release; its secretion is regulated predominantly by the cholinergic pathway, which inhibits somatostatin and thus stimulates gastrin release.
Negative_regulation (inhibits) of somatostatin associated with somatostatin
8) Confidence 0.51 Published 1986 Journal Scand. J. Gastroenterol. Suppl. Section Abstract Doc Link 2876506 Disease Relevance 0.10 Pain Relevance 0.57
Sumatriptan significantly decreased the mean plasma levels of somatostatin, glucagon, pancreatic polypeptide, insulin and C-peptide (P < 0.001) and also significantly decreased mean and peak plasma levels of insulin after an oral glucose challenge (P < 0.02 and P = 0.04, respectively) without affecting glucose homeostasis.
Negative_regulation (decreased) of somatostatin in plasma associated with sumatriptan and somatostatin
9) Confidence 0.44 Published 1998 Journal Am. J. Physiol. Section Abstract Doc Link 9486164 Disease Relevance 0.09 Pain Relevance 0.69
In rats, a postmortem delay of up to 8 hours did not affect SP, Met-Enk, PHI, or NPY and decreased SST, CCK, and VIP levels.
Neg (not) Negative_regulation (decreased) of SST associated with somatostatin, cholecystokinin and substance p
10) Confidence 0.42 Published 1990 Journal Neurology Section Abstract Doc Link 2296359 Disease Relevance 0.17 Pain Relevance 0.76
No beneficial effect of somatostatin was found in all included RCTs [52,53] on somatostatin after pancreatic surgery [see Additional file 2].
Neg (No) Negative_regulation (effect) of somatostatin associated with somatostatin
11) Confidence 0.42 Published 2009 Journal Trials Section Body Doc Link PMC2726965 Disease Relevance 0.22 Pain Relevance 0.32
To overcome the limitations of the octapeptides having affinity only to somatostatin receptor subtypes 2 and 5, HRPC expressing mainly somatostatin receptors 1 and 4, a somatostatin derivative based on the natural somatostatin having affinity to all five somatostatin receptor subtypes, was developed.
Negative_regulation (derivative) of somatostatin associated with somatostatin and reprotox - general 1
12) Confidence 0.42 Published 2004 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 15650261 Disease Relevance 0.51 Pain Relevance 0.41
These include aspirin and other non-steroidal antiinflammatory drugs (NSAIDs), selective cyclooxygenase inhibitors, somatostatin analogs, selective estrogen receptor modulators (SERMs), and anti-androgenic agents.
Negative_regulation (inhibitors) of somatostatin associated with aspirin, inflammation, somatostatin and cinod
13) Confidence 0.42 Published 2003 Journal Int J Gastrointest Cancer Section Abstract Doc Link 12909736 Disease Relevance 0.97 Pain Relevance 0.23
To overcome the limitations of the octapeptides having affinity only to somatostatin receptor subtypes 2 and 5, HRPC expressing mainly somatostatin receptors 1 and 4, a somatostatin derivative based on the natural somatostatin having affinity to all five somatostatin receptor subtypes, was developed.
Negative_regulation (derivative) of somatostatin associated with somatostatin and reprotox - general 1
14) Confidence 0.42 Published 2004 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 15650261 Disease Relevance 0.50 Pain Relevance 0.41
To overcome the limitations of the octapeptides having affinity only to somatostatin receptor subtypes 2 and 5, HRPC expressing mainly somatostatin receptors 1 and 4, a somatostatin derivative based on the natural somatostatin having affinity to all five somatostatin receptor subtypes, was developed.
Negative_regulation (derivative) of somatostatin associated with somatostatin and reprotox - general 1
15) Confidence 0.42 Published 2004 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 15650261 Disease Relevance 0.50 Pain Relevance 0.41
Capsaicin-sensitive neurones release a number of neuropeptides, such as substance P, neurokinin A, somatostatin and calcitonin gene-related peptide (CGRP), which exert a number of effects on smooth muscle tissues.
Negative_regulation (number) of somatostatin in smooth muscle tissues associated with qutenza, somatostatin, neuropeptide, calcitonin gene-related peptide and substance p
16) Confidence 0.42 Published 1999 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9932722 Disease Relevance 0 Pain Relevance 0.79
Efficacy in depression may be related to actions in man that take time or chronic drug administration to develop, such as increases in plasma tryptophan, decreases in CSF somatostatin, decreases in thyroid indices, and increases in urinary free cortisol excretion and, in animals, increases in substance P sensitivity and increases in brain adenosine receptors.
Negative_regulation (decreases) of somatostatin in brain associated with adenocard, depression, somatostatin and substance p
17) Confidence 0.42 Published 1988 Journal J Clin Psychiatry Section Abstract Doc Link 3280560 Disease Relevance 0.43 Pain Relevance 0.87
This report demonstrates secretin stimulation and somatostatin inhibition of gastrin secretion from a cell that is apparently not of endocrine origin.
Negative_regulation (inhibition) of somatostatin associated with somatostatin
18) Confidence 0.41 Published 1989 Journal Gastroenterology Section Abstract Doc Link 2473000 Disease Relevance 0.58 Pain Relevance 0.17
It can be hypothesized that clonidine does not elicit GH secretion decreasing hypothalamic somatostatin tone.
Negative_regulation (decreasing) of somatostatin associated with somatostatin and clonidine
19) Confidence 0.41 Published 1992 Journal Horm. Metab. Res. Section Abstract Doc Link 1398465 Disease Relevance 0.07 Pain Relevance 0.61
OBJECTIVE: We tested the possibility that lysine vasopressin (LVP) changes the GH responsiveness to exogenously administered GH-RH (at its minimal and maximal doses), clonidine (which is thought to stimulate endogenous GH-RH release) and arginine (which is thought to inhibit somatostatin) in patients with type 1 diabetes mellitus and normal subjects.
Negative_regulation (inhibit) of somatostatin associated with diabetes mellitus, somatostatin and clonidine
20) Confidence 0.41 Published 1999 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 10583317 Disease Relevance 0.17 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox